Jorunn Stamnaes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jorunn Stamnaes has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Ludvig M. Sollid
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, Norway
14 shared publications- Rasmus Iversen
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
10 shared publications - Ludvig M. Sollid
Norwegian Coeliac Disease Research Centre, Institute of Clinical Medicine, University of Oslo
9 shared publications - Knut Erik Aslaksen Lundin
Norwegian Coeliac Disease Research Centre, University of Oslo
4 shared publications - Shuo-Wang Qiao
Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
4 shared publications Asbjørn Christophersen
KG Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway
3 shared publications
Latest Publications
- Open Access
Mass spectrometry imaging-based explainable machine learning reveals the biochemical landscapes of the mouse brain
Recent computational advances in mass spectrometry imaging (MSI) now enable unprecedented insight into organ-wide molecular composition and functional architecture. Here, we present the first high-resolution molecular-computational atlas of specific mouse brain lipids and metabolites, acquired using a NEDC matrix and negative-mode MSI, covering 123 anatomically defined regions and 191 polygonal annotations derived solely from MSI data, without auxiliary imaging. To over-come annotation ambiguity and MSI complexity, we introduced the Computational Brain Lipid Atlas (CBLA), a graph-based visual-explainability framework that generates Virtual Landscape Visualizations (VLVs) of specific lipid distributions across brain substructures. The CBLA integrates dimensionality reduction and ensembles of supervised models to (i) refine annotations, (ii) elucidate interregional relationships, (iii) interpret model behavior, and (iv) formulate biologically testable hypotheses. The CBLA revealed novel lipid distribution patterns, functional integrations, anatomical connections – the brain’s telephone cables, and region-specific disease signatures – index lipids, including disease networks in the basal ganglia. It further identified index lipids that trace extrapyramidal nuclei and their cortical-brainstem connections, highlighting network-level molecular organization. A new algorithm decomposes annotated regions into precise m/z features and resolves high-resolution m/z values from MSI data, producing a comprehensive high-resolution brain map. It can be applied to any MS measurements, including metabolites, lipids, and peptides. This resource underpins down-stream studies, as exemplified here by characterizing the molecular lipid composition of A β plaques, their spatial arrangement, and their connections with surrounding tissue. For the first time, our data suggest that GM3 accumulation in cortical amyloid plaques may originate from hippocampal structures, consistent with longstanding evidence of disrupted hippocampocortical connectivity; a similar origin may also apply to plaque-associated A β signals in the cortex. More broadly, several selected m/z signals showed putative anatomical origins in specific brain subregions. Highlights: Mass spectrometry imaging (MSI) data were used to generate high-resolution, truthful visualizations for brain-region annotation without additional modalities. MSI data were further used to build a computational atlas of annotated brain regions. Pathological structures reveal both their origins and effects on specific brain networks. Anatomical regions and functional networks exhibit distinct lipid/metabolite patterns. Brainstem nuclei and white matter exhibit distinct lipid/metabolite compositions, indicating their involvement in pathological networks. Atlas-based Virtual Landscape Visualizations (VLVs) enable comparison of region-specific differences across mouse models. Several plaque-associated m/z signals, including GM3-related species, show putative hippocampocortical anatomical origins. Extrapyramidal nuclei and their cortical-brainstem connections are characterized by shared index lipids, enabling network-level molecular tracing.
Open AccessMass spectrometry imaging-based explainable machine learning reveals the biochemical landscapes of the mouse brain
Recent computational advances in mass spectrometry imaging (MSI) now enable unprecedented insight into organ-wide molecular composition and functional architecture. Here, we present the first high-resolution molecular-computational atlas of specific mouse brain lipids and metabolites, acquired using a NEDC matrix and negative-mode MSI, covering 123 anatomically defined regions and 191 polygonal annotations derived solely from MSI data, without auxiliary imaging. To over-come annotation ambiguity and MSI complexity, we introduced the Computational Brain Lipid Atlas (CBLA), a graph-based visual-explainability framework that generates Virtual Landscape Visualizations (VLVs) of specific lipid distributions across brain substructures. The CBLA integrates dimensionality reduction and ensembles of supervised models to (i) refine annotations, (ii) elucidate interregional relationships, (iii) interpret model behavior, and (iv) formulate biologically testable hypotheses. The CBLA revealed novel lipid distribution patterns, functional integrations, anatomical connections – the brain’s telephone cables, and region-specific disease signatures – index lipids, including disease networks in the basal ganglia. It further identified index lipids that trace extrapyramidal nuclei and their cortical-brainstem connections, highlighting network-level molecular organization. A new algorithm decomposes annotated regions into precise m/z features and resolves high-resolution m/z values from MSI data, producing a comprehensive high-resolution brain map. It can be applied to any MS measurements, including metabolites, lipids, and peptides. This resource underpins down-stream studies, as exemplified here by characterizing the molecular lipid composition of A β plaques, their spatial arrangement, and their connections with surrounding tissue. For the first time, our data suggest that GM3 accumulation in cortical amyloid plaques may originate from hippocampal structures, consistent with longstanding evidence of disrupted hippocampocortical connectivity; a similar origin may also apply to plaque-associated A β signals in the cortex. More broadly, several selected m/z signals showed putative anatomical origins in specific brain subregions. Highlights: Mass spectrometry imaging (MSI) data were used to generate high-resolution, truthful visualizations for brain-region annotation without additional modalities. MSI data were further used to build a computational atlas of annotated brain regions. Pathological structures reveal both their origins and effects on specific brain networks. Anatomical regions and functional networks exhibit distinct lipid/metabolite patterns. Brainstem nuclei and white matter exhibit distinct lipid/metabolite compositions, indicating their involvement in pathological networks. Atlas-based Virtual Landscape Visualizations (VLVs) enable comparison of region-specific differences across mouse models. Several plaque-associated m/z signals, including GM3-related species, show putative hippocampocortical anatomical origins. Extrapyramidal nuclei and their cortical-brainstem connections are characterized by shared index lipids, enabling network-level molecular tracing.
- Open Access
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
IFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.
- 19 August 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (20)
Open AccessIFN-γ is a direct driver of crypt hyperplasia in celiac disease
Crypt hyperplasia is a key feature of celiac disease (CeD) and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry–based tissue proteomics revealed a strong IFN-γ signal in active CeD. This signal, hallmarked by increased expression of MHC molecules, was paralleled by diminished expression of proteins associated with fatty acid metabolism. Crypt hyperplasia and the same proteomic changes were observed in WT mice administered IFN-γ. In mice with conditional KO of the IFN-γ receptor in gut epithelial cells, these signature morphological and proteomic changes were not induced with IFN-γ administration. IFN-γ was thus a driver of crypt hyperplasia in CeD by acting directly on crypt epithelial cells. The results are relevant to other enteropathies with involvement of IFN-γ.
- Open Access
- 30 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (5) , 758-765.e8
Biopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease
- 30 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (5) , 758-765.e8
Open AccessBiopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease
- Open Access
- 11 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (3) , 493-504.e10
Biopsy Proteome Scoring to Determine Mucosal Remodeling in Celiac Disease
- 11 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (3) , 493-504.e10
Open AccessBiopsy Proteome Scoring to Determine Mucosal Remodeling in Celiac Disease
- Open Access
- 3 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0259082
TG2-gluten complexes as antigens for gluten-specific and transglutaminase-2 specific B cells in celiac disease
A hallmark of celiac disease is the gluten-dependent production of antibodies specific for deamidated gluten peptides (DGP) and the enzyme transglutaminase 2 (TG2). Both types of antibodies are believed to result from B cells receiving help from gluten-specific CD4+T cells and differentiating into antibody-producing plasma cells. We have here studied the collaboration between DGP- and TG2-specific B cells with gluten-specific CD4+T cells using transgenic mice expressing celiac patient-derived T-cell and B-cell receptors, as well as between B-cell transfectants and patient-derived gluten-specific T-cell clones. We show that multivalent TG2-gluten complexes are efficient antigens for both TG2-specific and DGP-specific B cells and allow both types of B cells to receive help from gluten-specific T cells of many different specificities.
- 3 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0259082
Open AccessTG2-gluten complexes as antigens for gluten-specific and transglutaminase-2 specific B cells in celiac disease
A hallmark of celiac disease is the gluten-dependent production of antibodies specific for deamidated gluten peptides (DGP) and the enzyme transglutaminase 2 (TG2). Both types of antibodies are believed to result from B cells receiving help from gluten-specific CD4+T cells and differentiating into antibody-producing plasma cells. We have here studied the collaboration between DGP- and TG2-specific B cells with gluten-specific CD4+T cells using transgenic mice expressing celiac patient-derived T-cell and B-cell receptors, as well as between B-cell transfectants and patient-derived gluten-specific T-cell clones. We show that multivalent TG2-gluten complexes are efficient antigens for both TG2-specific and DGP-specific B cells and allow both types of B cells to receive help from gluten-specific T cells of many different specificities.
- Open Access
- 11 October 2021
- Published by Wiley in Proteomics
- Vol. 21 (23-24) , 2100057
Insights from tissue “omics” analysis on intestinal remodeling in celiac disease
Celiac disease (CeD) is a prevalent intestinal disorder that only develops in genetically susceptible individuals when they mount a harmful CD4+ T‐cell response towards gluten peptides. Intake of gluten leads to inflammation and remodeling of the small intestine with symptoms such as nausea and diarrhea. The only current treatment is a lifelong gluten free diet. The immunological basis for CeD is well characterized but the mechanisms that drive intestinal remodeling are still poorly understood. Transcriptome or proteome analysis of intestinal biopsies gives a global snapshot of all processes that occur in the tissue, including alterations in the epithelial cell layer. This paper will introduce concepts of intestinal remodeling, recapitulate the current understanding of CeD pathogenesis and discuss findings from relevant tissue “omics” studies. On the basis of this review, I give perspectives on what tissue “omics” studies can tell us about disease pathogenesis with a particular focus on the gluten induced intestinal remodeling.
- 11 October 2021
- Published by Wiley in Proteomics
- Vol. 21 (23-24) , 2100057
Open AccessInsights from tissue “omics” analysis on intestinal remodeling in celiac disease
Celiac disease (CeD) is a prevalent intestinal disorder that only develops in genetically susceptible individuals when they mount a harmful CD4+ T‐cell response towards gluten peptides. Intake of gluten leads to inflammation and remodeling of the small intestine with symptoms such as nausea and diarrhea. The only current treatment is a lifelong gluten free diet. The immunological basis for CeD is well characterized but the mechanisms that drive intestinal remodeling are still poorly understood. Transcriptome or proteome analysis of intestinal biopsies gives a global snapshot of all processes that occur in the tissue, including alterations in the epithelial cell layer. This paper will introduce concepts of intestinal remodeling, recapitulate the current understanding of CeD pathogenesis and discuss findings from relevant tissue “omics” studies. On the basis of this review, I give perspectives on what tissue “omics” studies can tell us about disease pathogenesis with a particular focus on the gluten induced intestinal remodeling.
- Open Access
- 4 January 2021
- Published by Wiley in Advanced Science
- Vol. 8 (4)
In Well‐Treated Celiac Patients Low‐Level Mucosal Inflammation Predicts Response to 14‐day Gluten Challenge
In celiac disease (CeD), gluten activates adaptive immune cells that cause damage to the small intestinal mucosa. Histological evaluation of intestinal biopsies allows for grading of disease severity. CeD can effectively be treated with a life‐long gluten‐free diet. Gluten challenge of treated CeD patients is used to confirm diagnosis and to test drug efficacy in clinical trials, but patients respond with different magnitudes to the same gluten challenge. In this study of 19 well‐treated CeD patients, proteome analysis of total tissue or isolated epithelial cell compartment from formalin‐fixed paraffin embedded biopsies collected before and after 14‐day gluten challenge demonstrates that patients with strong mucosal response to challenge have signs of ongoing tissue inflammation already before challenge. This low‐level tissue inflammation at baseline is paralleled by increased gluten specific CD4+ T‐cell frequencies in the gut and presence of a low‐level blood inflammatory profile. Thus, apparently well‐treated CeD is frequently not entirely quiescent, with presence of low‐grade inflammation and antigluten immunity in the gut mucosa. Histology assessment alone appears insufficient to judge full recovery and gut mucosal healing of CeD patients. The findings raise a concern whether a seemingly proper gluten‐free diet is able to curb gut inflammation in all CeD patients.
- 4 January 2021
- Published by Wiley in Advanced Science
- Vol. 8 (4)
Open AccessIn Well‐Treated Celiac Patients Low‐Level Mucosal Inflammation Predicts Response to 14‐day Gluten Challenge
In celiac disease (CeD), gluten activates adaptive immune cells that cause damage to the small intestinal mucosa. Histological evaluation of intestinal biopsies allows for grading of disease severity. CeD can effectively be treated with a life‐long gluten‐free diet. Gluten challenge of treated CeD patients is used to confirm diagnosis and to test drug efficacy in clinical trials, but patients respond with different magnitudes to the same gluten challenge. In this study of 19 well‐treated CeD patients, proteome analysis of total tissue or isolated epithelial cell compartment from formalin‐fixed paraffin embedded biopsies collected before and after 14‐day gluten challenge demonstrates that patients with strong mucosal response to challenge have signs of ongoing tissue inflammation already before challenge. This low‐level tissue inflammation at baseline is paralleled by increased gluten specific CD4+ T‐cell frequencies in the gut and presence of a low‐level blood inflammatory profile. Thus, apparently well‐treated CeD is frequently not entirely quiescent, with presence of low‐grade inflammation and antigluten immunity in the gut mucosa. Histology assessment alone appears insufficient to judge full recovery and gut mucosal healing of CeD patients. The findings raise a concern whether a seemingly proper gluten‐free diet is able to curb gut inflammation in all CeD patients.
- Open Access
- 1 August 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (2) , 788-790
Evidence That Pathogenic Transglutaminase 2 in Celiac Disease Derives From Enterocytes
- 1 August 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (2) , 788-790
Open AccessEvidence That Pathogenic Transglutaminase 2 in Celiac Disease Derives From Enterocytes
- Open Access
Quantitative proteomics of coeliac gut during 14-day gluten challenge: low-level baseline inflammation despite clinical and histological normality predicts subsequent response
Objective: To shed light on gut mucosa processes provoked by gluten exposure in coeliac disease, we performed a quantitative proteomic analysis of duodenal tissue from well-treated coeliac patients before and after gluten challenge. Design: We extracted and digested proteins from formalin-fixed paraffin-embedded tissue of 19 coeliac disease patients who had been challenged orally with gluten for 14 days. Protein identification and quantification was done by label-free quantitative mass spectrometry-based proteomics from total tissue and from laser capture microdissected epithelial cell layer. Proteomics data were compared with clinical, serological and histological data. Results: At baseline, all patients were in clinical and mucosal remission (Marsh 0-1) except one (Marsh 3). After challenge, five patients reached Marsh 3 scores. Proteome analysis categorised these five and additionally two patients as responders. Already at baseline, responder patients differed from the remaining patients in their gut tissue protein composition with altered levels of inflammatory and enterocyte function proteins – the same proteins that changed upon gluten challenge. Patients classified as responders from the proteomic analysis also differed from the remaining patients at baseline, with mild crypt hyperplasia and a slight increase in blood inflammatory parameters and gluten specific CD4+ T-cell frequencies. Conclusion: Despite clinical and histological remission, coeliac disease patients that develop a mucosal response after 14-day gluten challenge have already at baseline altered protein compositions of their gut tissue with signs of ongoing inflammation. Thus, apparently well-treated coeliac disease is frequently not fully quiescent with presence of low-grade anti-gluten immunity in gut mucosa.
Open AccessQuantitative proteomics of coeliac gut during 14-day gluten challenge: low-level baseline inflammation despite clinical and histological normality predicts subsequent response
Objective: To shed light on gut mucosa processes provoked by gluten exposure in coeliac disease, we performed a quantitative proteomic analysis of duodenal tissue from well-treated coeliac patients before and after gluten challenge. Design: We extracted and digested proteins from formalin-fixed paraffin-embedded tissue of 19 coeliac disease patients who had been challenged orally with gluten for 14 days. Protein identification and quantification was done by label-free quantitative mass spectrometry-based proteomics from total tissue and from laser capture microdissected epithelial cell layer. Proteomics data were compared with clinical, serological and histological data. Results: At baseline, all patients were in clinical and mucosal remission (Marsh 0-1) except one (Marsh 3). After challenge, five patients reached Marsh 3 scores. Proteome analysis categorised these five and additionally two patients as responders. Already at baseline, responder patients differed from the remaining patients in their gut tissue protein composition with altered levels of inflammatory and enterocyte function proteins – the same proteins that changed upon gluten challenge. Patients classified as responders from the proteomic analysis also differed from the remaining patients at baseline, with mild crypt hyperplasia and a slight increase in blood inflammatory parameters and gluten specific CD4+ T-cell frequencies. Conclusion: Despite clinical and histological remission, coeliac disease patients that develop a mucosal response after 14-day gluten challenge have already at baseline altered protein compositions of their gut tissue with signs of ongoing inflammation. Thus, apparently well-treated coeliac disease is frequently not fully quiescent with presence of low-grade anti-gluten immunity in gut mucosa.
- Open Access
- 14 November 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (2)
B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2
Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient–derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2−/− mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2−/− mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten–TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.
- 14 November 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (2)
Open AccessB cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2
Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient–derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2−/− mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2−/− mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten–TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.